publication date: Dec. 20, 2010

In this issue: 

ODAC votes 9-6 in favor of Clolar for pediatric acute lymphoblastic leukemia, but votes against Marqibo for non-Hodgkin’s lymphoma.

Also NCI prostate SPOREs plan biospecimen bank.

NCI advisors seek comment on clinical trials system, until Jan. 15.

NCI funds 17 EDRN biomarker labs. Bush signs omnibus funding legislation.

Dept. of Defense opens program announcements for prostate cancer research.

Children’s Cancer Research Institute at UT Health Science Center recruits faculty.

Two cancer center directors named: Michael Kastan at St. Jude, James Willson at Harold Simmons.

December issue of Business & Regulatory Report included (an additional 8 pages of industry news).

Next issue of The Cancer Letter is scheduled for Jan. 7, 2005.

Download (PDF 960KB)

To access this members-only content, please log in.
Institutional subscribers, please log in with your IP.
If you're not a subscriber why not join today?
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.
Click here to join.

Copyright (c) 2020 The Cancer Letter Inc.